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ABSTRACT
Purpose: The aim of this study was to gain more knowledge on how people with rheumatoid
arthritis (RA) experienced participation in a randomized controlled trial (RCT) testing the
effect of a smoking cessation intervention since this intervention have not been tested on
an RA population before
Methods: We conducted a qualitative study with semi-structured individual interviews with
12 participants from the intervention group in the RCT.
Results: Through thematic analysis we identified four themes: Instilling hope for smoking
cessation, referring to the initial invitation to participate in the RCT; Various components of
importance in the intervention, referring to cooperation with the smoking cessation coun-
sellor, improved carbon monoxide levels, fear of becoming addicted to nicotine replacement
therapy, and suggestions for additional components in the intervention which could promote
motivation; Breaking habits, referring to ongoing reflection on quitting smoking; and
Increased awareness of health, arthritis and smoking, referring to the lack of information
on smoking and RA from health professionals, and the impact of smoking on RA symptoms
and overall health.
Conclusion: The results reflect the participants’ perspective on what is meaningful to them
when trying to quit smoking and adds important knowledge to future smoking cessation
studies in this patient group.
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Introduction
Smoking is one of the most significant modifiable
environmental risk factors for rheumatoid arthritis
(RA) (Manfredsdottir et al., 2006; Scott, Wolfe, &
Huizinga, 2010). Studies suggest that 25–30% of peo-
ple with RA in Denmark smoke (Loppenthin et al.,
2015; Primdahl, Clausen, & Horslev-Petersen, 2013).
This is almost twice as many as in the background
population in Denmark (Sundhedsstyrelsen, 2018).
Smoking may exacerbate the progression of RA and
reduce the effect of antirheumatic treatment
(Abhishek, Butt, Gadsby, Zhang, & Deighton, 2010;
Chang et al., 2014; Soderlin, Petersson, & Geborek,
2012; Vittecoq, Richard, Banse, & Lequerre, 2018).
Furthermore, smokers with RA experience higher dis-
ease activity compared to non-smokers with RA
(Nyhall-Wahlin, Petersson, Nilsson, Jacobsson, &
Turesson, 2009). This indicates that smoking cessation
could be crucial for the treatment effect and disease
outcomes of RA.
Successful long-term smoking cessation is usually
achieved by several attempts of quitting before success
(Chaiton et al., 2016; Tobacco Use and Dependence
Clinical Practice Guideline Panel, 2000). Smoking cessa-
tion interventions have been demonstrated to be effec-
tive in healthy individuals, people who are hospitalized,
and people with chronic obstructive pulmonary disease
(COPD) and cardiovascular diseases (CVD) (Barth, Jacob,
Daha, & Critchley, 2015; Rigotti, Clair, Munafo, & Stead,
2012; Stead et al., 2013; Stead & Lancaster, 2012; van
Eerd, van der Meer, van Schayck, & Kotz, 2016). The
interventions include behavioural support, nicotine
replacement therapy (NRT), a combination of beha-
vioural support and NRT, and prescription medication.
Several Cochrane reviews conclude that the most effec-
tive smoking cessation intervention for both healthy
individuals and people with COPD and CVD is beha-
vioural support and NRT (Barth et al., 2015; Stead &
Lancaster, 2012; van Eerd et al., 2016). We lack evidence
regarding the optimal interventionintensity andduration
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required for smoking cessation(Stead & Lancaster, 2012).
A recent review found that increased behavioural sup-
port increase the chance of successful smoking cessation
by up to 20% (Stead, Koilpillai, & Lancaster, 2015).
However, another study showed that, although brief
advice for people with RA increased their awareness of
the link between smoking and RA, it did not increase
smoking cessation rates (Harris, Tweedie, White, &
Samson, 2016). Studies of smoking cessation interven-
tions for people with RA are sparse.
Currently we are carring out a randomized con-
trolled trial (RCT) testing the effect of an intensive
smoking cessation intervention on smoking cessation
and disease activity in people with RA (Roelsgaard
et al., 2017). The intervention consists of behavioural
support and NRT to current smokers with RA
(Roelsgaard et al., 2017). We wished to evaluate how
participants experienced the intervention provided in
the RCT and the experiences of smoking cessation. We
wished to explore the patients’ experience of the inter-
vention regardless of whether they stopped smoking
or not. We were therefore eager to gain insight into the
perspectives of both those who stopped smoking and
those who did not stop smoking. Furthermore, we also
wished to explore the patients’ knowledge of the detri-
mental effects of smoking on RA and its treatment. This
knowledge can guide further development of smoking
cessation interventions for these patients.
Therefore, the aim of this study was to gain more
knowledge on how people with RA experienced par-
ticipation in an RCT testing the effect of a smoking
cessation intervention since this intervention have not
been tested on an RA population before.
Materials and methods
Design and study setting
This study employed a descriptive qualitative design
involving people with RA who had participated in an
international RCT, that tested the effect of an intensive
smoking cessation intervention on smoking cessation
and disease activity in smokers with RA (NCT02901886)
(Roelsgaard et al., 2017). The intervention arm consisted
of a smoking cessation intervention with five smoking
cessation counselling sessions combined with free NRT
for six weeks. Furthermore, we measured carbon mon-
oxide levels in exhaled breath at least one time during
the intervention. The content of the counselling sessions
is described in detail in Table I. The people in the control
arm received standard care i.e., no smoking cessation
counselling or NRT. All participants from the RCT
had four follow-up visits within 58 weeks, with various
measurements e.g., RA-specific outcomes, cardiovascular
outcomes and patient-reported outcomes (e.g., pain,
health-related quality of life, flare and disease activity).
Participants
Participants were recruited consecutively from the inter-
vention group in the RCT after having completed both
the intervention and the three months follow-up visit.
Successful smoking cessation was not an inclusion cri-
terion, hence both quitters and non-quitters were asked
to participate. Eligible patients were informed about the
project both orally and in writing, and invited to parti-
cipate either by telephone or face-to-face at the Centre
for Rheumatology and Spine Diseases outpatient clinic,
Rigshospitalet. The median age of the participants was
62 years, 6 females and 6 males participated, and the
median years of smoking was 46.5 years. Additional
participant characteristics are described in Table II.
Data collection
In total, 12 patients accepted the invitation to participate
in the study, and agreed to participate. Individual, semi-
structured interviews were performed at the Centre for
Rheumatology and Spine Diseases, Rigshospitalet,
Glostrup between February and July 2018 (lasting
between 45 and 75 minutes, mean 60 minutes) by BAE,
who had no prior involvement with or knowledge of the
participants.
Semi-structured individual interviews were con-
ducted using an interview guide that was developed
Table I. The intervention in the RCT—consisting of five sessions with a smoking cessation counsellor in combination with
nicotine replacement therapy.
Meeting Themes
1. An introduction to the counselling course and preparation for smoking cessation, including the participant’s smoking status and their
motivation for cessation.
A diary is handed out to help the participant keep track of smoking pattern.
2. Aims to prepare the participant for the three first days without smoking. A plan for nicotine replacement therapy (NRT) is made and the
participant is given the agreed form of NRT.
A diary is handed out to help the participant keep track of smoking pattern and NRT use.
3. Aims to help the participant with issues concerning quitting smoking, including risk situations, relapse, rewards, social network and
smoking stop.
A diary is handed out to help the participant keep track of smoking pattern and NRT use.
4. Includes maintaining motivation, physical activity, handling of stress and mood swings.
A diary is handed out to help the participant keep track of smoking pattern and NRT use.
5. (final) Includes continuing help with smoking cessation and preparation for the time after the intervention, phasing out NRT, and measurement of
carbon monoxide in exhaled breath.
A diary is handed out to help the participant keep track of smoking pattern and NRT use.
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to elicit the participants’ experiences of participating
in the RCT and the smoking cessation intervention
(Table III).
The interview guide was based on the elements of
the intervention in the RCT and previous studies of
smoking cessation interventions, and motivation and
barriers to smoking cessation (Aimer et al., 2018,
2015). The interview guide helped the interviewer
(BAE) to ensure that coverage of all desired areas
related to the aim of the study.
Patient research partner
A PRP with RA, who was a former smoker, was actively
involved throughout the conduct of the study accord-
ing to the principles of respect and equality between
PRP and researchers (de Wit et al., 2011; Hewlett et al.,
2006; Trivedi & Wykes, 2002). The PRP participated in
developing the interview guide, interpretation of the
analysis and results as well as commented and
approved the final version of the manuscript.
Analysis
The interviews were recorded digitally and transcribed
verbatim. All transcripts were uploaded to NVivo (ver-
sion 11, QSR International) for a structured analysis.
Latent thematic analysis was applied, as described by
Braun and Clarke (Braun & Clarke, 2006), by continuously
asking: “In what way did the participants talk about their
experience of the randomized controlled trial and inten-
sive smoking cessation intervention?” The approach was
inductive, which entailed that the themes were strongly
connected to the raw data. The analysis was a six-phase
process (Braun & Clarke, 2006).
Initially [1], we became familiarized with data by
listening to the interviews and comparing them to
the transcribed interviews.Then [2], we generated
initial codes based on the interview guide, and [3]
organized the codes and searched for initial themes.
Thereafter [4], we reviewed the themes by comparing
them with one another. Then [5], we defined, redefined
and labelled the themes, and finally [6] we wrote up
the results and included vivid examples from the data-
extract (Braun & Clarke, 2006). The initial analysis was
performed by the first author (IKR) in close collabora-
tion with TT, BAE and a patient research partner (PRP).
During the analysis, we continuously supplemented
and contested each other’s statements to ensure the
results were grounded in the participants’ experiences.
Ethics
The study was approved by the Danish Data Protection
Agency (RH-2017-274, I-suite 05814) and carried out
according to the principles of the Helsinki Declaration.
Participants provided signed informed consent prior to
the interviews. All data were treated confidentially and
stored according to current legislation.
Results
From the interviews, we identified four themes and six
sub-themes through thematic analysis (Table IV). The aim
of this study was to gain knowledge on how the partici-
pants experienced participation in the RCT. From the
analysis we learned that the patients wanted to stop
smoking and the invitation to participate in the RCT
induced hope for successful smoking cessation. They
experienced thedifferent components in the intervention
to be important for smoking cessation, however, smoking
cessation nevertheless proved difficult. The patients
expressed that health professionals should inform
patients about the detrimental effects of smoking on RA.
Theme 1: instilling hope for smoking cessation
The participants saw the project as an opportunity to
quit smoking and the project instilled hope of achieving
smoking cessation. The participants felt it was positive
that health staff from the Department of Rheumatology
were interested in helping them stop smoking.
There were participants who were happy to be part
of the intervention group of the RCT, as it gave them
extra motivation for smoking cessation.
Table II. Participant characteristics.
Characteristics N = 12
Age, median (range) 62 (33–71)
Female, n (%) 6 (50)
Married/cohabiting, n (%) 10 (83.3)
Years of school attendance, median (range) 1 (0–5)
Current connection to labour market, n (%) 8 (66.7)
Duration of RA, median (range) 12 (2–28)
Fagerstöms Nicotine Dependence, median (range) 4.5 (2–8)
Current smoker, n (%) 10 (83.3)
Non-smokers, n (%) 2 (16.6)
Age at smoking debut, median (range) 14.5 (12–18)
Years of smoking, median (range) 46.5 (17–57)
Number of cigarettes per day, median (range) 17.5 (15–20)
Pack years, median (range) 39.5 (12.75–57)
Number of previous quitting attempts, median
(range)
2.5 (0–8)
Table III. The interview guide.
Opening question
What do you know about smoking and rheumatoid arthritis?
1: Smoking history
Please, tell me about your experiences of smoking?
2: Smoking and arthritis
Which considerations do you have about smoking and your health now
and in the future?
3: Participation in the randomized controlled trial
What were your reasons for participating in the study?
4: Content in the intervention
How did you experience the smoking cessation sessions?
5: Motivation and barriers
What motivation and barriers have you experienced in the process?
Closure
If a further study were to be undertaken, what ddo you think it should
include?
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“YES, I thought, now I have all the opportunities, and
now you really have to grab it, and just do it, and then
we we’ll see how it goes … ” Interview J.
One said that he would have preferred to be in the
control group, so he could continue as usual and take
“the easy way”. Some did not think they would be
able to give up smoking if they were in the control
group, because they would be on their own without
support; they felt that, with less focus on their smok-
ing consumption, their motivation would be
challenged.
Theme 2: various components of importance in
the intervention
Sub-theme 2a: having a fellow traveller on the
road to smoking cessation
The participants had an experience of being greeted
positively and not being looked down upon during
the intervention. This was highlighted as very impor-
tant, as otherwise they would just have backed out of
the project—as they expressed it. Not giving up on
smoking during the trial was described it this:
“Yes, I was embarrassed that I hadn’t quit, but
I wasn’t … looked down upon for that reason. They
were sweet and nice towards me and encouraged me,
even though I had not stopped, which I think was nice.”
Interview A.
The positive attitude of the smoking cessation coun-
sellor was emphasized and this made it easier to get
back on track if they had a setback. The principles of
the intervention were perceived as non-judgemental,
which motivated participants to make an effort and
attend the following counselling session. The length
of the counselling sessions was considered adequate.
The participants experienced that they were very
engaged while the intervention was ongoing and
that it was reassuring to know one had an appoint-
ment with the smoking cessation counsellor in the
future if there had been set-backs in the smoking
cessation process.
The diaries the participants were given to note
their tobacco and NRT consumption, were considered
helpful, both in the beginning and when the smoking
cessation went well. However, the diaries became
a burden when giving up smoking was not going
well, because set-backs or increases in cigarette con-
sumption were clearly documented.
“Yes, yes, but there is also the thing, that it gets to you
at home when you know that in a few weeks you will
have to go there and be account for it again, and hand
in your written notes of how many you have smoked …
Yes, but I actually think it is a good thing that every
evening when filling out the notes you are confronted
with how it went, because otherwise you wouldn’t
count … ” Interview L.
Sub-theme 2b: carbon monoxide levels as
a motivational factor
It was motivating to see carbon monoxide levels
improving. The benefits of smoking cessation became
tangible as the participants were not necessarily able
to feel any effects of the smoking cessation or reduc-
tion of cigarette consumption on their health or RA. It
was considered satisfying to follow the development
themselves and the carbon monoxide results moti-
vated their next attempt to give up smoking because
they had seen how quickly the numbers improved.
“Well, I was VERY impressed. Everything was improved.
That made me really happy and I also thought: ‘This
here can get you to continue’.” Interview A
Sub-theme 2c: apprehension—fear of a new
dependence
As part of the intervention, the participants were
offered NRT. Some participants were afraid of becoming
addicted to NRT and therefore were reluctant to use it.
“ … And I think it is because the nicotine, I have not
had the nicotine for almost four months now … And
I think that was what I was most afraid of, which I have
convinced myself to believe … That I was most afraid of
the nicotine … I was afraid of the addiction.”
Interview J.
There were participants who tried different variants of
NRT. Some described that they got unwell with the
chewing gum and that the mouth spray tasted bad.
Some of the participants did not experience any
effects of the NRT. However, the participants ulti-
mately settled on a variant of NRT that suited them.
Sub-theme 2d: suggestions for additional elements
in the intervention
The participants provided ideas for further develop-
ment of the intervention, for example, the inclusion of
text messages and emails. Personalized messages
could boost motivation because one would be
reminded of the smoking cessation more frequently.
Table IV. Themes identified in the analysis.
Theme Subtheme
1. Instilling hope for smoking
cessation
2. Various components of
importance in the
intervention
2a. Having a fellow traveller on the
road to smoking cessation
2b. Carbon monoxide levels in exhaled
breath as a motivational factor
2c. Apprehension—fear of a new
dependence
2d. Suggestions for additional
elements in the intervention
3. Breaking habits
4. Increased awareness of
health, arthritis and
smoking
4a. Why wasn’t I told?
4b. The effect of smoking cessation on
arthritis and general health
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Participants varied as to whether they would prefer
individual or group sessions. The advantage of group
sessions could be inspiration and ideas from other
group members, while individual sessions meant
that you had to do the “project” all by yourself.
Opinions also varied regarding the potential bene-
fit of having a partner participate in the intervention
with you. On the positive side, this would allow parti-
cipants to compete with their partner, which might
increase motivation. Negatives could include the
effect if the partner did not wholeheartedly go along
with the intervention or interfered too much. Finally,
some participants called for more counselling sessions
in order to increase their success in quitting smoking.
“I just think that there could have been a few more
conversations … Yes, then I think that I could have quit
completely … Had there been a few more conversations
then I am pretty sure it would have motivated me to
stop completely … .” Interview C.
Theme 3: breaking habits
Those who did not give up smoking described that
their participation in the smoking cessation counsel-
ling sessions made them more aware of their smoking
habits during and after the intervention.
“Ohh, some more focus on that. And some more of,
what is it called … That the cigarette you just smoked,
you smoked automatically, now I’m more focused on
not smoking on autopilot … So, now I’m more aware of
the unnecessary cigarettes—if you can use a stupid
term like that, so yes.” Interview B
Participants slowly developed other habits, which
they linked with the smoking cessation counselling.
For example, if one could not see the cigarettes then
one might forget them for a while. Some described
that they had an improved insight into themselves in
relation to risk situations and that this was helpful in
the smoking cessation process.
“Yes, but it is about getting to know myself in these
situations and to get a handle on what exactly are the
situations where I am emotionally pressured and
remain focused on giving up smoking.” Interview H.
Theme 4: increased awareness of health, arthritis
and smoking
Sub-theme 4a: why wasn’t I told?
Some of the participants had spoken to their rheuma-
tologist about the negative side effects of smoking in
relation to arthritis. None of the participants had spo-
ken to a nurse about smoking and RA. The partici-
pants expressed that they needed more education on
the link between smoking and RA and support for
smoking cessation was brought up more regularly
by both rheumatologists and nurses, specifically the
effects smoking has on RA. Some were aware that
smoking and RA were a negative combination, while
others did not link RA and smoking. They wanted
more knowledge about when they would be able to
see improvement in their RA symptoms after smoking
cessation.
“The only thing I’ve never really had any information
about is what smoking does to rheumatoid arthritis. I’ve
never really got to know about that”. Interview A
Sub-theme 4b: the effect of smoking cessation on
arthritis and general health
The participants did not experienced improvement in
their RA disease activity subsequent to smoking ces-
sation or reduced cigarette consumption.
“It is really hard to measure. That is, when you are
already sick. Is it the disease or is it the smoking or
what is it that makes you feel worse or better? …
Because the arthritis goes up and down like crazy …
Yes. It is strange. In the evening or in the morning I can
feel really good. And then in the afternoon I can’t
walk … Oh, yes, the ever-changing disease. It’s up
and down, you know” Interview D.
There were participants who felt a exacerbation in the
RA after quitting andcould not help connecting the
smoking cessation with the worsening of RA, but
nevertheless knew that it was unlikely that the two
things were related. It was disappointing as smoking
had always been portrayed as negative by the rheu-
matologist, resulting in the feeling of solely responsi-
bility for the aggressive disease activity. It was
described that the rheumatologist had promised
that the RA would improve if one stopped smoking.
“Yes, in some ways it is nice, but on the other hand
I usually like to say that none of my doctors have
experienced having rheumatoid arthritis … but he can
still not predict when I will get better … He promised
me that if I gave up smoking then my arthritis would
get better. ” Interview J.
Some experienced improved health after giving up
smoking or cutting back on cigarettes and described
that they felt healthier. This feeling was mainly due to
being able to breathe more easily and that was the
most motivating part of the smoking cessation
process.
“I mean, yes that was nice. I mean it was lovely, you
know. I could feel, apart from my rheumatoid arthritis
that I felt an improvement in my health, you know. Like
better breathing and a feeling of being a bit healthier. ”
Interview E.
Discussion
The results of this study highlight that the offer of an
intensive smoking cessation intervention was mean-
ingful to people with RA. All the elements of the
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intervention—from the initial information about the
study, the randomization, the different elements of
the intervention, including motivational interviewing,
diaries, NRT, and carbon monoxide measurements—
were experienced as relevant by the patients. Overall,
the participants expressed a positive attitude to the
trial and the intervention because it instilled a hope
for possible smoking cessation.
Participating in the intervention was considered to
be a positive and motivational experience, because
of the motivation generated with the smoking cessa-
tion counsellor and because carbon monoxide levels
were monitored. The intervention in the RCT study
(Roelsgaard et al., 2017) aimed to help people iden-
tify possible barriers to smoking cessation, and
explore and overcome these barriers by focusing on
something positive through motivational interview-
ing (MI) (Miller, 2002). Motivational is the keyword in
MI, the concept on which the counselling sessions
were based. This ensured that a positive approach
was taken to the patients. The motivational factors
could be both external and internal. External motiva-
tors included the interaction with the smoking cessa-
tion counsellor, monitoring of carbon monoxide
levels, accountability through the diaries and NRT
(which, for some, was considered to be a barrier).
Internal motivators were the exploration of their
ambivalence towards smoking cessation and the
conscious decision to stop smoking (Miller, 2002).
This is supported by a Cochrane review, demonstrat-
ing that motivational interviewing provided by gen-
eral practitioners or by trained counsellors is more
effective in helping smokers to quit smoking than is
brief advice (Lindson-Hawley, Thompson, & Begh,
2015). Even if most of the participants in the current
study did not succeed in quitting, they described the
counselling sessions as motivating both during the
intervention and for future quit attempts. This sug-
gested that that the intervention positively influ-
enced the participants’ awareness of their smoking
habits even though they did not stop smoking. This
could potentially improve their chances of
a successful smoking cessation in the future, due to
an increased awareness of the process, including
barriers and risk situations, related to smoking
cessation.
The participants expressed a need for more inten-
sive smoking cessation support, for example more
counselling sessions, emails and or SMS support.
Some participants specifically expressed a need for
an increased number of counselling sessions to quit
smoking. This could be explained by a wish for more
responsibility from the smoking cessation counsellor,
as some expressed that they felt highly committed to
the counsellor. However, the wish for more sessions is
more likely to be an expression of not wanting to be
“left alone” on the journey to smoking cessation—as
also expressed through participants’ appreciation of
having a fellow traveller on the journey to cessation.
A higher amount of support was investigated in
a pilot RCT by Aimer et al., who examined a tailored
3-month smoking cessation intervention consisting of
behavioural support, email consultations and NRT
(Aimer et al., 2017). The quit rates at 6-months follow-
up were relatively high (overall 24%) (Aimer et al.,
2017). NRT and brief advice were also provided to
people in the control group, possibly explaining the
high quit rates in the control group. The different
wishes and needs among the participants in our cur-
rent study and Aimer’s study could be helpful in
designing future smoking cessation interventions for
people with RA. These studies indicate that the inter-
ventions lasting longer than the intervention offered
to participants in the current study should be tested.
All participants, in the intervention and control
groups, had their carbon monoxide level measured
at baseline, throughout the intervention and at fol-
low-up. It was a general perception among the parti-
cipants that they were motivated by the ongoing
monitoring of carbon monoxide levels. The partici-
pants were enthralled by the immediate improvement
in carbon monoxide levels, even if they could not feel
the effect in their bodies. Monitoring of carbon mon-
oxide levels in smoking cessation studies has pre-
viously been demonstrated to be motivational and
has been reported in RCTs that tested carbon mon-
oxide levels as a support and motivation for smoking
cessation (Sejourne et al., 2010; Shahab, West, &
McNeill, 2011). Carbon monoxide measurements
therefore appear to be an important tool for sustain-
ing motivation.
Some participants were fearful of becoming
addicted to NRT. They feared that their smoking
addiction would be replaced by an addiction to NRT.
Some also had not experienced any effect of the NRT
during previous quit attempts and therefore did not
wish to try it again. It appeared that some participants
wished to go “cold turkey” to avoid a new addiction
to NRT, as also described in a qualitative study based
on an internet forum for smoking cessation (Kurko,
Linden, Kolstela, Pietila, & Airaksinen, 2015). In that
study, participants expressed a negative attitude
towards NRT, as they believed its use maintained
tobacco dependence (Kurko et al., 2015).
Apprehension towards the use of NRT may be
a substantial barrier to successful smoking cessation.
However, there is compelling evidence that NRT
increases the chances of long-term smoking cessation
by 50–70% (Silla, Beard, & Shahab, 2014; Stead et al.,
2012). We therefore consider it crucial that smoking
cessation counsellors educate smokers about NRT and
encourage its use. In future studies, the effect of other
types of pharmacotherapy, such as bupropion, vareni-
cline and cytisine should therefore be examined in
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people with RA who smokes (Cahill, Stevens, Perera, &
Lancaster, 2013).
Reflections on the association between smoking and
RA varied among our participants. Many did not believe
there was any connection between the two and felt no
improvement in their RA after having cut down or com-
pletely quitting smoking. We do not know the time
period from smoking cessation to a possible improve-
ment of RA symptoms. Therefore, we could not inform
patients of what to expect. To our surprise, the partici-
pants did not mention their RA disease much in the
interviews which could be explained by a possible lack
of knowledge about the link between smoking and RA.
Qualitative studies have previously identified that one of
the main barriers to smoking cessation in patients with
RA and systemic lupus erythematosus was lack of
knowledge of the links between smoking and RA
(Aimer et al., 2015; Gath, Stamp, Aimer, Stebbings, &
Treharne, 2018; Wattiaux et al., 2019). In those studies,
patients expressed that they had not received informa-
tion from their rheumatologist about the association
between smoking and RA (Aimer et al., 2015; Wattiaux
et al., 2019). However, awareness of the effects of smok-
ing on RA could be motivate smoking cessation (Gath
et al., 2018). The participants in our study asked for more
information from health professionals about smoking,
smoking cessation and the connection to RA. We do not
know from our study to what degree participants were
informed about the relation between RA and smoking.
In Denmark, health professionals are obliged to talk to
their patients about smoking and its negative impact. It
remains unclear to what degree this is actually done.
Nevertheless, the lack of awareness about the risks of
smoking and RA is important knowledge, which can
inform future planning.
There are several strengths of the current study.
Firstly, the same person interviewed all the participants,
ensuring homogeneity throughout the interviews.
Furthermore, the interviewer was not involved in the
intervention of the trial and had not previously been in
contact with the participants, thereby reducing the risk
of bias and ensuring the external validity of the study.
Secondly, there were equal numbers ofmale and female
participants, whereas most studies including people
with RA show a higher proportion of women (as RA is
more frequent in women). Finally, all the invited patients
agreed to participate in this qualitative study. This is
particularly interesting because some of those who
accepted to participate did not quit smoking.
Nevertheless, they were willing to share their experi-
ences, which was of great importance,because they
had perceived participation in the RCT to be a positive
experience.
It could be argued that a limitation of this study
was the inclusion of participants only from the inter-
vention group (which was our aim). They were all
positive about the project and felt that they had
received help and support during their quit attempt.
This might not have been the case had we included
patients from the control group, however we wish to
evaluate the intervention as well.
The results of the current study increase our insight
into patients’ experiences of an intensive smoking cessa-
tion intervention. Patients were, overall, content with
participating in the RCT and the intervention. The results
suggest that gaining the patients’ trust is an important
factor in their motivation to stop smoking. Even though
several did not quit smoking, they portrayed the RCT
and intervention as a positive experience that gave them
tools for future smoking cessation attempts. The partici-
pants were motivated to stop smoking but most did not
manage to quit. This could imply that motivation alone
is not enough to succeed and that factors such as
nicotine addiction and the fear of becoming addicted
to NRT may be a strong barriers to smoking cessation.
In conclusion, the patients called for more focus by
health professionals on smoking cessation. Smoking
cessation counselling should be offered at the clinics
where the patients are treated for RA. Smoking cessation
is complex and the participants in our study encouraged
health professionals to address and talk more about
smoking and smoking cessation with patients. Future
clinical studies that would test various types of smoking
cessation interventions should includemore counselling
sessions and be of a longer duration, in order to improve
the chances of quitting smoking among people with RA.
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